These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25452444)

  • 1. Reply to P.S.N. van Rossum et al and J. Shapiro et al.
    Mariette C; Robb WB
    J Clin Oncol; 2015 Jan; 33(3):289. PubMed ID: 25452444
    [No Abstract]   [Full Text] [Related]  

  • 2. Critical appraisal of locoregional failure and systemic disease progression after preoperative chemoradiation of esophageal adenocarcinoma. Reply to R. Gertler et al.
    Sudo K; Elimova E; Skinner HD; Hofstetter WL; Ajani JA
    J Clin Oncol; 2014 Jul; 32(19):2112-3. PubMed ID: 24868018
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to E. C. Smyth et al.
    Mamon HJ; Tepper JE
    J Clin Oncol; 2014 Sep; 32(27):3082. PubMed ID: 25071102
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to E. C. Smyth et al.
    Hulshof MC; Oppedijk V; van der Gaast A
    J Clin Oncol; 2014 Sep; 32(27):3081-2. PubMed ID: 25071131
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiac volume effects during chemoradiotherapy for esophageal cancer (Regarding Lutkenhaus et al. Reduction in cardiac volume during chemoradiotherapy for patients with esophageal cancer).
    Edmunds K; Brooks C; Hansen VN; Harris V; Tait DM
    Radiother Oncol; 2015 Jan; 114(1):128-9. PubMed ID: 25497875
    [No Abstract]   [Full Text] [Related]  

  • 6. Regarding Edmunds et al. Cardiac volume effects during chemoradiotherapy for esophageal cancer.
    Lutkenhaus LJ; Kamphuis M; van Wieringen N; Hulshof MC; Bel A
    Radiother Oncol; 2015 Jan; 114(1):130. PubMed ID: 25583569
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to J. Zhang et al.
    Bohanes P; Yang D; Lenz HJ
    J Clin Oncol; 2013 Feb; 31(6):816-7. PubMed ID: 23544202
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comment apropos of the article "Esophageal cancer: did combined treatment improve prognosis?" by G. Ganem et al].
    Bosset JF; Gignoux M; Elias D; Triboulet JP; Mantion G; Rougier P
    Bull Cancer; 1993 Mar; 80(3):261-4. PubMed ID: 8173179
    [No Abstract]   [Full Text] [Related]  

  • 9. Systematic overview of preoperative chemoradiation trials in esophageal cancer: in response to article by Ian Geh et al.
    Srinivas C; Laskar SG; Mistry RC; Pramesh CS; Dinshaw KA
    Radiother Oncol; 2007 Jan; 82(1):106-7; author reply 107-8. PubMed ID: 17156874
    [No Abstract]   [Full Text] [Related]  

  • 10. Residual tumor after neoadjuvant chemoradiation outside the radiation therapy target volume: a new prognostic factor for survival in esophageal cancer: in regard to Muijs et al.
    Gemici C
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):715. PubMed ID: 25304953
    [No Abstract]   [Full Text] [Related]  

  • 11. Moving palliative care from research to practice: commentary on Uitdehaag et al.
    Given CW
    J Pain Symptom Manage; 2014 Mar; 47(3):515. PubMed ID: 24269031
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Letter: "The Role of Surgery for Patients With a Complete Clinical Response After Chemoradiation for Esophageal Cancer".
    Mariette C; Robb WB; Piessen G
    Ann Surg; 2015 Dec; 262(6):e101-2. PubMed ID: 24670853
    [No Abstract]   [Full Text] [Related]  

  • 13. Reply to the Comment on: Hölscher AH, Bollschweiler E, Bogoevski D, Schmidt H, Semrau R, Izbicki JR. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer – A propensity score matched analysis. Eur J Cancer. 2014;50(17):2950-7.
    Bollschweiler E; Hölscher AH
    Eur J Cancer; 2015 Sep; 51(14):2097-8. PubMed ID: 26187512
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to J. Beyer, T. Tandstad et al, S. Gillessen et al, J. Oldenburg et al, and L.C. Pagliaro et al.
    Vaughn DJ
    J Clin Oncol; 2015 Jul; 33(20):2324-5. PubMed ID: 26033814
    [No Abstract]   [Full Text] [Related]  

  • 15. In reply to Gemici.
    Muijs CT; Beukema JC; Langendijk JA; Plukker JT
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):715-6. PubMed ID: 25304954
    [No Abstract]   [Full Text] [Related]  

  • 16. Reply to: Definitive chemoradiation for oesophageal cancer--a standard of care in patients with non-metastatic oesophageal cancer.
    Doulami G; Theodorou D
    Clin Oncol (R Coll Radiol); 2011 Nov; 23(9):653; author reply 653. PubMed ID: 21798730
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to s. Bonovas et Al, s. Clement et Al, and j.L. Lund et Al.
    Tsan YT; Lee CS; Ho WC; Lin MH; Wang JD; Chen PC
    J Clin Oncol; 2013 Nov; 31(32):4162-4. PubMed ID: 24081943
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Shoemark
    Amirav I; Lavie M
    Am J Respir Crit Care Med; 2020 Jan; 201(1):123-125. PubMed ID: 31433954
    [No Abstract]   [Full Text] [Related]  

  • 19. Postoperative complications do not affect long-term outcome in esophageal cancer patients: reply.
    Lindner K; Fritz M; Haane C; Senninger N; Palmes D; Hummel R
    World J Surg; 2015 May; 39(5):1322-4. PubMed ID: 25631941
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to Letter: "Residual Esophageal Cancer After Neoadjuvant Chemoradiotherapy Frequently Involves the Mucosa and Submucosa".
    Shapiro J; Wijnhoven BP; van Lanschot JJ
    Ann Surg; 2015 Aug; 262(2):e84-5. PubMed ID: 24743617
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.